Found 22 results
Author [ Title(Desc)] Type Year
Filters: Author is Schmidt, C  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
M
G. Mutua, Mutengu, L., Mpendo, J., Kilembe, W., Omosa, G., Ruzagirwa, E., Karita, E., Page-Shipp, L., Gray, G., Bekker, L. G., Barin, B., Schmidt, C., Laufer, D., and Priddy, F., Major Negative Social Impacts are Rare in Phase 1 HIV Vaccine Trials in Africa, in HIV Research for Prevention 2014: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P), Cape Town, SA, 2014.
P
S. Vasan, Schlesinger, S., Chen, Z., Hurley, A., Lombardo, A., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Boente-Carrera, M., Schmidt, C., Fang, Q., Ba, L., Huang, Y., Zaharatos, G., Gardiner, D., Caskey, M., Seamons, L., and Ho, M., Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 Clade B'/C Candidate Vaccine, PLOS One, vol. 5, p. e8816, 2010.
S. Vasan, Schlesinger, S., Huang, Y., Hurley, A., Lombardo, A., Chen, Z., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Schmidt, C., Song, Y., Seamons, L., Dally, L., Ho, M., Smith, C., Markowitz, M., Cox, J., Gill, D., and Gilmour, J., Phase 1 Safety and Immunogenicity Evaluation of ADVAX a Multigenic, DNA-Based Clade C/B’ HIV-1 Candidate Vaccine, PLoS ONE, vol. 5, p. e8617, 2010.
S. Mehendale, van Lunzen, J., Clumeck, N., Rockstroh, J., Vets, E., Johnson, P. R., Anklesaria, P., Barin, B., Boaz, M., Kochhar, S., Lehrman, J., Schmidt, C., Peeters, M., Schwarze-Zander, C., Kabamba, K., Glaunsinger, T., Sahay, S., Thakar, M., ,, and Heald, A., A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C Adeno-Associated Virus Vaccine, AIDS Research and Human Retroviruses, vol. 24, pp. 873-880, 2008.
E. Vardas, Kaleebu, P., Bekker, L., Hoosen, A., Chomba, E., Johnson, P., Anklesaria, P., Birungi, J., Barin, B., Boaz, M., Cox, J., Lehrman, J., Stevens, G., Gilmour, J., Tarragona, T., Hayes, P., Lowenben, S., Kizito, E., Fast, P., Heald, A., and Schmidt, C., A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Vaccine Based on Adeno-Associated Virus, AIDS Res Hum Retroviruses, vol. 26, pp. 933-942, 2010.
E. Vardas, Kaleebu, P., Bekker, L., Hoosen, A., Chomba, E., Johnson, P., Heald, A., Anklesaria, P., Dally, L., Boaz, M., Fast, P., and Schmidt, C., A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant Adeno-Associated Virus HIV Vaccine, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
B. Peters, Jaoko, W., Anzala, O., Judges, L., G Manyonyi, O., Sharp, A., Gray, K., Fast, P., Schmidt, C., Gilmour, J., Smith, C., Dally, L., Loughran, K., Farah, B., Tarragona, T., Hayes, P., McMichael, A., Hanke, T., and Bwayo, J., Phase 2A Dose and Route Study of a DNA Prime MVA Boost Vaccine Candidate, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
I. Cebere, Dorrell, L., McShane, H., Simmons, A., McCormack, S., Schmidt, C., Smith, C., Brooks, M., Roberts, J. E., Darwin, S. C., Fast, P. E., Conlon, C., Rowland-Jones, S., McMichael, A. J., and Hanke, T., Phase I Clinical Trial Safety of DNA- and Modified Virus Ankara-Vectored Human Immunodeficiency Virus Type 1 (HIV-1) Vaccines Administered Alone and in a Prime-Boost Regime to healthy HIV-1 Uninfected Volunteers, Vaccine, vol. 24, pp. 417-425, 2006.
S
F. Nakwagala, Birungi, J., Schmidt, C., Nanvubya, A., Konde, C., Hughes, P., Mugisha, E., Johnson, B., Muluubya, A., Nielsen, L., Gilmour, J., Gibiansky, L., Smith, C., Fast, P., and Kaleebu, P., Safety and immunogenicity of HIV-1 clade A vaccines in healthy, HIV uninfected adult Ugandan volunteers, 2004.
E. Vardas, Pantaleo, G., Bart, P. A., Robinson, A., Pieterse, C., Thomas, R., McIntyre, J., Gray, G., Bogoshi, M., Mayaphi, S., Fast, P., Schmidt, C., Gilmour, J., Tarragona, T., Smith, C., and Dally, L., Safety and Immunogenicity of MVA.HIVA by 3 Different Routes, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
W. Jaoko, Kayitenkore, K., G Manyonyi, O., Karita, E., Schmidt, C., Fast, P., Komaroff, W., Cooper, A., Boaz, M., Gilmour, J., Dally, L., Ho, M., Smith, C., and Graham, B., Safety and Immunogenicity of VRC Multiclade HIV-1 Adenoviral Vector Vaccine Alone or with VRC Multiclade HIV-1 DNA Plasmid Vaccine in the African Adults, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
S. Vasan, Hurley, A., Schlesinger, S., Hannaman, D., Gardiner, D., Dugin, D., Huang, Y., Andersen, J., Caskey, M., Evans, C., Dolter, K., Schmidt, C., Fast, P., and Ho, D., Safety, Tolerability, and Acceptability of Electroporation to Deliver ADVAX, a Clade C/B’ DNA-Based Candidate HIV-1 Vaccine, to Healthy Volunteers, in AIDS Vaccine 2008 Conference, Cape Town, South Africa, 2008.
B. S. Peters, Jaoko, W., Vardas, E., Panayotakopoulos, G., Fast, P., Schmidt, C., Gilmour, J., Bogoshi, M., G Manyonyi, O., Dally, L., Klavinskis, L., Farah, B., Tarragona, T., Bart, P. - A., Robinson, A., Pieterse, C., Stevens, W., Thomas, R., Barin, B., and Bwayo, J. [..], Studies of a Prophylactic HIV-1 Vaccine Candidate Based on Modified Vaccinia Virus Ankara (MVA) with and without DNA Priming: Effects of Dosage and Route on Safety and Immunogenicity, Vaccine, vol. 25, pp. 2120-2127, 2007.